Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11141699 | 0.89 | MAPT (0.49) | CYP3A4CLK1GSK3BDYRK1ACLK4 | |
| SCHEMBL5891799 | 0.89 | CYP3A4 (0.50) | CYP3A4CLK1GSK3BDYRK1ACLK4 | |
| SCHEMBL6206050 | 0.89 | CYP3A4 (0.49) | CYP3A4CLK1GSK3BDYRK1ACLK4 | |
| SCHEMBL5426133 | 0.87 | ALDH1A1 (0.46) | CYP3A4CLK1GSK3BDYRK1ACLK4 | |
| SCHEMBL27237644 | 0.83 | GAA (0.51) | CYP3A4MAPK1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL231446 | 0.80 | GPR35 (0.45) | MAPK1SMN1; SMN2KDM4EMAPTPKM | |
| SCHEMBL68918 | 0.79 | MAPT (0.45) | CYP3A4MAPK1SMN1; SMN2ERN1KDM4E | |
| SCHEMBL15199259 | 0.79 | GPR35 (0.56) | MAPK1KDM4EMAPTPKMMEN1 | |
| SCHEMBL4069709 | 0.77 | TPMT (0.64) | CYP3A4MAPK1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL9732800 | 0.77 | ALDH1A1 (0.50) | CLK1GSK3BDYRK1ACLK4DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862730-B2 | Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-09 | — | — | US | disclosed |
| US-9862730-B2 | Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-09 | — | — | US | disclosed |
| EP-2847200-B1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-2847200-B1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20150133446-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | UNIVERSITE DE MONTREAL (CA) | 2015-05-14 | — | — | US | disclosed |
| US-20150133446-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | UNIVERSITE DE MONTREAL (CA) | 2015-05-14 | — | — | US | disclosed |
| US-20150133446-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | UNIVERSITE DE MONTREAL (CA) | 2015-05-14 | — | — | US | disclosed |
| EP-2847200-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013163244-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013163244-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| CN-1274685-C | Benzimidazol derivatives modulate che mokine receptors | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | CN | disclosed |
| WO-2006067311-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) SAS (FR) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135573-A1 | Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof | IPSEN PHARMA S.A.S. (FR) | 2006-06-22 | — | — | US | disclosed |
| EP-1641789-A2 | BENZOTHIAZOLE-4,7-DIONES AND BENZOXAZOLE-4,7-DIONES WITH SUBSTITUENTS IN POSITION 5 OR 6 AND METHOD FOR PRODUCTION THEREOF | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005000843-A2 | BENZOTHIAZOLE-4,7-DIONES AND BENZOXAZOLE-4,7-DIONES WITH SUBSTITUENTS IN POSITION 5 OR 6 AND METHOD FOR PRODUCTION THEREOF | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-01-06 | — | — | WO | disclosed |
| CN-1509281-A | Benzimidazol derivatives modulate che mokine receptors | — | 2004-06-30 | — | — | CN | disclosed |
| US-20040116435-A1 | Benzimidazol derivatives modulate chemokine receptors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| EP-1373248-A1 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002074763-A9 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002074763-A1 | BENZIMIDAZOL DERIVATIVES MODULATE CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133446-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, F2RL1 | CYP3A4 89/4885CLK1 3359/4885GSK3B 1150/4885 |
| US-20060135573-A1 | Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof | CDC25A, CDC25C, CDC25B | CYP3A4 416/4885CLK1 1838/4885GSK3B 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.